• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Ocular Therapeutix, Inc. - Common Stock (NQ:OCUL)

    7.335 +0.045 (+0.62%)
    Delayed Quote Updated: 9:39 AM EDT, Oct 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 162,266
    Open 7.400
    Bid (Size) 7.330 (500)
    Ask (Size) 7.340 (300)
    Prev. Close 7.290
    Today's Range 7.300 - 7.425
    52wk Range 6.230 - 16.44
    Shares Outstanding 157,749,490
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    3 Reasons to Avoid OCUL and 1 Stock to Buy Instead
    Over the last six months, Ocular Therapeutix’s shares have sunk to $7.74, producing a disappointing 7.1% loss - a stark contrast to the S&P 500’s 16.6% gain.... 
    Via StockStory
    Topics Stocks
    Let's uncover which stocks are experiencing notable gaps during today's session. ↗
    Via Chartmill

    Performance

    YTD
    -37.9%
    -37.9%
    1 Month
    -30.6%
    -30.6%
    3 Month
    -23.9%
    -23.9%
    6 Month
    -13.6%
    -13.6%
    1 Year
    -33.6%
    -33.6%

    More News

    Read More
    News headline image
    Ocular Therapeutix and ANI Pharmaceuticals Stocks Trade Down, What You Need To Know
    Via StockStory
    News headline image
    Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Success ↗
    Via MarketBeat
    Ocular Therapeutix Inc (NASDAQ:OCUL) Misses on Revenue and EPS in Q1 2026, Stock Dips ↗
    Via Chartmill
    News headline image
    1 Cash-Heavy Stock on Our Buy List and 2 Facing Challenges
    Via StockStory
    News headline image
    Pharmaceuticals Stocks Q2 Highlights: Ocular Therapeutix (NASDAQ:OCUL)
    Via StockStory
    Topics Artificial Intelligence Intellectual Property
    News headline image
    Ocular Therapeutix (NASDAQ:OCUL) Beats Expectations in Strong Q2 CY2026
    Via StockStory
    News headline image
    3 Healthcare Stocks with Questionable Fundamentals
    Via StockStory
    News headline image
    3 Russell 2000 Stocks That Concern Us
    Via StockStory
    News headline image
    Pharmaceuticals Stocks Q1 In Review: Ocular Therapeutix (NASDAQ:OCUL) Vs Peers
    Via StockStory
    Topics Artificial Intelligence Intellectual Property
    News headline image
    Ocular Therapeutix Eyes Q4 AXPAXLI NDA After FDA Alignment ↗
    Via MarketBeat
    News headline image
    3 Cash-Burning Stocks with Open Questions
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    3 Small-Cap Stocks with Open Questions
    Via StockStory
    News headline image
    Ocular Therapeutix (OCUL): Buy, Sell, or Hold Post Q1 Earnings?
    Via StockStory
    Topics Stocks
    News headline image
    Stocks making big moves yesterday: Nubank, Ocular Therapeutix, Mondelez, ResMed, and Sonos
    Via StockStory
    Topics Economy
    News headline image
    Why Ocular Therapeutix (OCUL) Stock Is Up Today
    Via StockStory
    News headline image
    Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026? ↗
    Via The Motley Fool
    News headline image
    3 of Wall Street’s Favorite Stocks That Concern Us
    Via StockStory
    News headline image
    1 Russell 2000 Stock to Research Further and 2 Facing Headwinds
    Via StockStory
    News headline image
    Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1 ↗
    Via The Motley Fool
    Topics Regulatory Compliance Stocks
    News headline image
    What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Why Ocular Therapeutix (OCUL) Stock Is Nosediving
    Via StockStory
    News headline image
    Ocular Therapeutix (NASDAQ:OCUL) Reports Sales Below Analyst Estimates In Q1 CY2026 Earnings
    Via StockStory
    News headline image
    Ocular Therapeutix (OCUL) To Report Earnings Tomorrow: Here Is What To Expect
    Via StockStory

    Frequently Asked Questions

    Is Ocular Therapeutix, Inc. - Common Stock publicly traded?
    Yes, Ocular Therapeutix, Inc. - Common Stock is publicly traded.
    What exchange does Ocular Therapeutix, Inc. - Common Stock trade on?
    Ocular Therapeutix, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Ocular Therapeutix, Inc. - Common Stock?
    The ticker symbol for Ocular Therapeutix, Inc. - Common Stock is OCUL on the Nasdaq Stock Market
    What is the current price of Ocular Therapeutix, Inc. - Common Stock?
    The current price of Ocular Therapeutix, Inc. - Common Stock is 7.335
    When was Ocular Therapeutix, Inc. - Common Stock last traded?
    The last trade of Ocular Therapeutix, Inc. - Common Stock was at 10/02/26 09:39 AM ET
    What is the market capitalization of Ocular Therapeutix, Inc. - Common Stock?
    The market capitalization of Ocular Therapeutix, Inc. - Common Stock is 1.16B
    How many shares of Ocular Therapeutix, Inc. - Common Stock are outstanding?
    Ocular Therapeutix, Inc. - Common Stock has 1B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.